αHER2‐SubA exhibited a high affinity for HER2‐expressing cancer cells (Kd = 21.5 nM), comparable to that of αHER2 alone (Kd = 19.8 nM), indicating its potential for effective targeting of breast cancer cells (Figure 8B). This evidence concerns the gene ERBB2 and breast carcinoma.